Skip to content

PRESS RELEASES


PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Integra LifeSciences Introduces Integra(R) Pocket Strip and Integra(R) Shaped Strip DBM Implants
Company's First DBM Implants Specifically Designed for Posterior Lumbar Spine Fusion Procedures
View HTML
Toggle Summary Integra LifeSciences Reports Third Quarter 2014 Financial Results
Revenue Increased 7.7% to $229.7 Million GAAP EPS was $0.30 Adjusted EPS Increased 16% to $0.76 Operating Cash Flow was $31.1 Million PLAINSBORO, N.J., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today reported its financial results for the third quarter
View HTML
Toggle Summary Integra LifeSciences Announces Strategic Portfolio Alignment and Plans to Create Stand-Alone Spine Business as a Separate Public Company
Plans to Spin Off Spine Business to Create SeaSpine, a New Publicly Traded Company, By Means of Tax-Free Distribution to Integra Shareholders Both Companies Will be Leaders in Providing Regenerative Technologies Integra to Operate as Two Global Divisions in 2015 Upon Completion of the Spin-Off:
View HTML
Toggle Summary Integra LifeSciences Completes the Acquisition of MicroFrance and Xomed Manual ENT and Laparoscopy Instrumentation Lines From Medtronic
PLAINSBORO, N.J., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it has completed the acquisition of the MicroFrance and Xomed manual ear, nose and throat (ENT) and laparoscopy instrumentation lines from Medtronic.
View HTML
Toggle Summary Integra LifeSciences to Host Its Third Quarter 2014 Earnings Results Conference Call on November 3, 2014
PLAINSBORO, N.J., Oct. 9, 2014 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) will release its third quarter 2014 financial results on Monday, November 3, 2014. The company has scheduled a conference call for 4:30 PM ET the same day to discuss the results.
View HTML
Toggle Summary Integra LifeSciences Announces Full Market Release for the Integra(R) Freedom Wrist Arthroplasty System
PLAINSBORO, N.J., Sept. 18, 2014 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the full commercial release of the Integra® Freedom Wrist Arthroplasty System in the United States. The system, which is used in the treatment of wrist arthritis, has been
View HTML
Toggle Summary Integra LifeSciences to Acquire Medtronic's MicroFrance and Xomed Manual ENT and Laparoscopy Instrumentation Lines
PLAINSBORO, N.J., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) and Medtronic, Inc. today announced an agreement in which Integra will acquire Medtronic's MicroFrance and Xomed manual ENT and laparoscopy instrumentation lines for approximately $60
View HTML
Toggle Summary Integra LifeSciences Announces Changes Within Its Orthopedics and Tissue Technologies Business
PLAINSBORO, N.J., Sept. 2, 2014 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it has made changes to the leadership of its Orthopedics and Tissue Technologies business. The new organization enables Integra to use its resources more efficiently in
View HTML
Toggle Summary Integra LifeSciences to Participate in the Morgan Stanley Global Healthcare Conference in September
PLAINSBORO, N.J., Aug. 21, 2014 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it will present at the following conferences next month: - At 10:35AM ET on Tuesday, September 9, 2014, Mr. Peter Arduini, Integra's President and Chief Executive
View HTML
Toggle Summary Integra LifeSciences Announces Completion of Its Multicenter Clinical Trial for the Treatment of Diabetic Foot Ulcers
PLAINSBORO, N.J., Aug. 5, 2014 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it has completed Its multicenter clinical trial evaluating the safety and effectiveness of INTEGRA® Dermal Regeneration Template for the Treatment of Diabetic Foot Ulcers
View HTML
Toggle Summary Integra LifeSciences Reports Second Quarter 2014 Financial Results
Revenue Increased 12.6% to a Record of $231 million Adjusted Diluted EPS Increased by 28% Free Cash Flow Increased by $17.7 million PLAINSBORO, N.J., Aug. 5, 2014 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today reported its financial results for the second quarter
View HTML
Toggle Summary Integra LifeSciences to Host Its Second Quarter 2014 Earnings Results Conference Call on August 5, 2014
PLAINSBORO, N.J., July 10, 2014 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) will release its second quarter 2014 financial results on Tuesday, August 5, 2014. The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results.
View HTML
Toggle Summary Integra LifeSciences Announces Renewal and Extension of Credit Facility
PLAINSBORO, N.J., July 9, 2014 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it has established new terms under its credit facility, including an increase in the size of the facility and an extended maturity date, with its bank group led by Bank of
View HTML
Toggle Summary Integra LifeSciences Celebrates 25th Anniversary
PLAINSBORO, N.J., June 19, 2014 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a world leader in medical technology, today announced that June 2014 marks the 25 th anniversary of its founding. Twenty-five years ago, Richard Caruso, PhD, currently a member of Integra's
View HTML
Toggle Summary Integra LifeSciences Announces Contract with Premier, Inc.
Will Provide Small Bone Orthopedic Implants
View HTML